ヨーロッパの多発性硬化症治療市場 – 業界動向と2030年までの予測

ヨーロッパの多発性硬化症治療市場の分析と規模

世界の医療制度に対するいくつかの感染症の負担の増大は主要な考慮事項であり、その負担の不均衡な部分を発展途上国が負っています。インドの肝臓胆道科学研究所によると、世界の人口の約 3% が主に C 型肝炎ウイルスに感染しています。特に先進国と発展途上国の両方で HCV 感染の発生率が世界的に増加していることが、多発性硬化症治療市場の成長につながる主な要因です。

Data Bridge Market Research の分析によると、多発性硬化症治療市場は 2030 年までに 102 億 116 万ドル、2022 年には 60 億 2670 万ドルに達し、2022 年から 2030 年の予測期間中に 6.8% の CAGR で成長すると予想されています。市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、Data Bridge Market Research がまとめた市場レポートには、詳細な専門家の分析、患者の疫学、パイプライン分析、価格分析、規制の枠組みも含まれています。

欧州の多発性硬化症治療市場の範囲とセグメンテーション

Market Definition

Multiple sclerosis (MS) is a chronic and inflammatory immune-mediated condition that can cause axonal transection, demyelination, and neurodegeneration of the spinal cord and brain nerve cells. Some of the frequently used therapies include the administration of injectable, oral and infused medicines, antidepressants, physical therapy and muscle relaxants.

Europe Multiple Sclerosis Treatment Market Dynamics

Drivers

• Rising Awareness About Multiple Sclerosis

There has been a rising awareness about the disease which is helping in boosting the market growth. For instance, the Multiple Sclerosis Foundation and affiliated groups have started National MS Education and Awareness Month, which is observed in March since 2003 to create awareness about the disease. The main aim of this program is to promote an understanding of multiple sclerosis disease and assist the patients in making educated decisions associated with its treatment. Furthermore, the National MS Society created and launched the “MS Kills Connection > < Connection Kills MS” campaign to connect people suffering from MS, people who treat MS patients, and people who run activities to create a world free of multiple sclerosis. Thus, this factor boosts the market growth.

• Increasing Occurrence of Multiple Sclerosis

There has been growing occurrences of multiple sclerosis in this region. According to the National Multiple Sclerosis Society’s study, an estimated prevalence of the disease was around 309 cases per 100,000 people in 2010, resulting in total of 727,344 multiple sclerosis cases among adults. Europe is considered a high prevalence region for MS. The Multiple Sclerosis Society stated that about 110,000 people were suffering from the condition in the U.K. in 2018. It is also witnessed that MS is more than twice incident in females in this region. The number of new patients diagnosed every year is also increasing, which means that the number rise from 5,000 patients in 2017 to 6,700 in 2018. Therefore, this incidence rate is boosting the demand for the treatment drugs.

Opportunities

• Increased R&D Activities by Organizations

Numerous drugs are in the research phase for the treatment of multiple sclerosis (MS) and many are undergoing clinical trials. U.S. FDA has approved several drugs for the treatment of MS namely fingolimod, interferons, natalizumab, glatiramer acetate, teriflunomide, and dimethyl fumarate. Several geneticists as well as other researchers are studying human genome for causes and other possible treatments for diseases such as muscular dystrophy, Alzheimer's, cancer and diabetes. For instance, they have found that some people with a specific gene are more likely to develop Alzheimer's disease. So researchers are now working on drugs that will modify or repair that particular gene. Likewise, many researchers have found that some people suffering from multiple sclerosis have a certain gene which makes them more vulnerable to the disease. Hence, they are now consistently working on drugs that will either alter or repair that gene.

Restraints/Challenges

• High cost of Drugs

The cost of multiple sclerosis drugs remains a constant challenge to the market growth despite of the high prevalence of multiple sclerosis. The high pricing of drugs makes it inefficient to meet the needs pf the affected population. DMTs are the standard option for treatment but the extreme cost of these drugs leads to the improper adherence and disease management. As per the National Multiple Sclerois Society, the cost of MS drugs are increasing hugely. This factor is anticipated to limit the market growth.

This multiple sclerosis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the multiple sclerosis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments:

• In 2021, Janssen received U.S. FDA approval for Ponvory. It is a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, that is used to treat adults with relapsing forms of multiple sclerosis (MS), such as clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.
• In 2020, Novartis announced that the US FDA approval for Kesimpta in the form of an injection for subcutaneous use for treating the relapsing forms of multiple sclerosis (RMS), which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Europe Multiple Sclerosis Treatment Market Scope

The multiple sclerosis treatment market is segmented on the basis of disease type, treatment, drug type, and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disease Type

• Relapsing–Remitting Multiple Sclerosis (RRMS)
• Secondary Progressive Multiple Sclerosis (SPMS)
• Primary Progressive Multiple Sclerosis (PPMS)
• Severe Relapsing–Remitting Multiple Sclerosis (RES)

Treatment

• Preventive Therapies
• Abortive Therapies/Treatment of Acute Exacerbations
• Symptomatic Therapies

Drug Type

• Branded
• Generic

Route of Administration

• Oral
• Parenteral

End-User

• Hospital and Clinics
• Diagnostic Laboratories
• Others

Multiple Sclerosis Treatment Regional Analysis/Insights

The multiple sclerosis treatment market is analyzed and market size insights and trends are provided by disease type, treatment, drug type and end-user as referenced above.

The countries covered in the multiple sclerosis treatment market report are Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.

Germany is expected to lead the market in the forecast period of 2023 to 2030 due to the introduction of brand new treatment options for multiple sclerosis in the region. The growing research and development for drug development in the region is also boosting the growth of the market. The increased awareness of people associated with multiple sclerosis and its treatment is helping in leading the market growth.  

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Europe Multiple Sclerosis Treatment Market Share Analysis

The multiple sclerosis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to multiple sclerosis treatment market.

多発性硬化症治療市場で活動している主要企業は次のとおりです。

• アッヴィ社（米国）
• バウシュ・ヘルス・カンパニーズ（カナダ）
• バイオラ・セラピューティクス社（米国）
• ベーリンガーインゲルハイムインターナショナルGmbh（ドイツ）
• アムジェン社（米国）
• ファイザー社（米国）
• F. ホフマン・ラ・ロシュ社（スイス）
• マイランNV（米国）
• ノバルティスAG（スイス）
• バイエルAG（ドイツ）
• ブリストル マイヤーズ スクイブ カンパニー (米国)
• バイオジェン（米国）
• テバ製薬工業株式会社（イスラエル）
• 武田薬品工業株式会社（日本）
• ジャズ・ファーマシューティカルズ社（英国）
• アボット（米国）
• バイオ・ラッド・ラボラトリーズ社（米国）
• マイランNV（米国）

SKU-56749